No registration fee. Preregistration is recommended for in-person attendance in Dallas/Irving as seating is limited. See the Location tab for hotel booking instructions.

---

 

Target Audience
This activity has been designed to meet the educational needs of medical oncologists, hematologists, hematology-oncology fellows, surgeons, radiation oncologists, pharmacists, nurse practitioners, clinical nurse specialists and other healthcare professionals involved in the treatment of cancer.

Learning Objectives
Lung Cancer
Upon completion of this activity, participants should be able to

• Evaluate available data documenting the efficacy and safety of anti-PD-1/PD-L1 antibody-based approaches as neoadjuvant, adjuvant or consolidation therapy for patients with nonmetastatic non-small cell lung cancer (NSCLC).
• Review published research documenting the efficacy of EGFR-directed treatment for localized, locally advanced and metastatic NSCLC with an EGFR tumor mutation, and apply this information in the care of appropriately selected patients.
• Communicate the efficacy and safety of approved ALK inhibitors to patients with localized and metastatic NSCLC for whom treatment with this approach would be appropriate.
• Recollect other oncogenic pathways, such as ROS1, RET, MET, HER2, KRAS and NTRK, mediating the pathogenesis of NSCLC in unique patient subsets, and recall published data with commercially available and experimental agents exploiting these targets.
• Consider recent therapeutic advances related to anti-PD-1/PD-L1 antibodies as monotherapy or in combination with other systemic therapies for metastatic NSCLC, and discern how these approaches can be employed in the management of this disease.
• Develop a long-term care plan for patients with progressive NSCLC, considering exposure to prior systemic therapy, performance status and personal goals of treatment.
• Design an optimal approach to the long-term care of patients with small cell lung cancer, considering available research findings and the implications of age, symptomatology, disease stage and other clinical factors.
• Reflect on investigational agents and strategies currently in testing for patients with lung cancer, and as applicable, refer eligible candidates for clinical trial participation.

Chronic Lymphocytic Leukemia (CLL)
Upon completion of this activity, participants should be able to

• Individualize the selection of systemic therapy for patients with newly diagnosed CLL, considering new research findings, clinical presentation, biomarker profile, coexisting medical conditions and preferences for time-limited or continuous treatment.
• Review the similarities and differences between covalent and noncovalent Bruton tyrosine kinase (BTK) inhibitors, and assess the implications for the efficacy and tolerability of these agents.
• Evaluate available and emerging Phase III data demonstrating the efficacy of covalent and noncovalent BTK inhibitors as first-line therapy for CLL, and use this information to counsel patients regarding front-line treatment options.
• Understand published research findings with Bcl-2 inhibitors in combination with anti-CD20 antibodies as first-line treatment for CLL, and counsel patients regarding the risks and benefits of this novel treatment strategy.
• Appreciate the scientific rationale for the investigation of combined BTK and Bcl-2 inhibition, and review recently presented data documenting the safety and efficacy of this strategy for patients with CLL.
• Analyze how age, performance status, prior therapeutic exposure and other biological and disease-related factors affect the selection and sequencing of therapy for patients with relapsed/refractory (R/R) CLL.
• Discuss available clinical research demonstrating the efficacy and safety of noncovalent BTK inhibitors for R/R CLL, and use this information to identify patients appropriate for treatment with these agents.
• Implement a plan of care to recognize and manage side effects and toxicities associated with available systemic therapies commonly employed in the management of CLL.
• Recall available and emerging data with novel agents and treatment strategies currently under investigation in CLL, and as applicable, refer eligible patients for clinical trial participation.

Ovarian Cancer (OC)
Upon completion of this activity, participants should be able to

• Understand available clinical research findings with PARP inhibitors as maintenance therapy after first-line platinum-based chemotherapy for advanced OC, and appropriately counsel patients regarding personalized treatment recommendations.
• Recognize the rationale for targeting folate receptor alpha in OC, determine optimal methods to test for this newly relevant biomarker and evaluate the role of novel approaches to therapeutically exploit it.
• Appreciate available and emerging clinical research findings with anti-PD-1/PD-L1 antibodies in combination with chemotherapy for patients with platinum-resistant OC, and consider the potential role of this novel therapeutic strategy.
• Understand the biological justification for the evaluation of selective glucocorticoid receptor modulators in combination with chemotherapy for patients with platinum-resistant OC, and recall available Phase III findings with this novel approach.
• Assess the incidence of cadherin-6 expression in OC, and understand the available data with and structural components and mechanism of action of novel antibody-drug conjugates directed at this target.
• Review published clinical research documenting the efficacy of HER2-targeted antibody-drug conjugates for HER2-overexpressing OC, and consider the role of this approach in the care of patients with this disease subtype.
• Describe the scientific justification for, published research data with and ongoing research studies of novel agents and strategies in OC, and effectively prioritize clinical trial opportunities for eligible patients.

Gastroesophageal Cancers
Upon completion of this activity, participants should be able to

• Evaluate recently presented clinical research findings to determine their effect on the current management of gastric, gastroesophageal junction (GEJ) and esophageal cancers.
• Recognize available clinical research findings with immune checkpoint inhibitors as neoadjuvant, adjuvant or perioperative therapy for patients with resectable gastric, GEJ and esophageal cancers, and consider the current and potential role of these approaches.
• Describe published research data with anti-PD-1/PD-L1 antibodies alone or in combination with other systemic therapies in the management of metastatic gastric, GEJ and esophageal cancer, and optimally integrate these strategies into nonresearch treatment algorithms.
• Assess available data with monoclonal antibody therapy directed at claudin 18.2 (CLDN18.2) in combination with chemotherapy as first-line treatment for patients with HER2-negative, CLDN18.2-positive gastric or GEJ cancer, and optimally incorporate this approach into management algorithms.
• Review published research findings with established HER2-targeted therapies for patients with HER2-positive gastroesophageal cancers, and assess the nonresearch role of various agents and regimens in treatment.
• Evaluate the scientific justification for the dual targeting of PD-1 and TIGIT in patients with gastroesophageal cancers, and appreciate available data with and ongoing trials investigating novel approaches.
• Review the rationale for, available data with and ongoing research studies evaluating novel agents and strategies for patients with gastroesophageal cancers in preparation for potential clinical availability or to enhance trial participation.

CE Credit
CME, ABIM MOC, ABS and ACPE credit information will be given to each participant as part of the meeting course materials.

NCPD Credit
To obtain a certificate of completion and receive credit for this event, nurses must attend the entire activity and return a completed Educational Assessment and Credit Form. A credit form link will be given to each participant as part of the meeting course materials.

CME Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CME Credit Designation Statement
Research To Practice designates this live activity for a maximum of 5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component and a post-test, enables the participant to earn up to 5 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialties: medical oncology and hematology.

American Board of Surgery (ABS) — Continuous Certification (CC)
Successful completion of this CME activity, which includes participation in the evaluation component and a post-test, enables the learner to earn up to 5 Medical Knowledge MOC points toward the CME and Self-Assessment requirement(s) of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABS credit.

Please note, this program has been specifically designed for the following ABS practice area: complex general surgical oncology.

NCPD Accreditation Statement
Research To Practice is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC).

NCPD Credit Designation Statements
This educational activity for 5 contact hours is provided by Research To Practice.
This activity is awarded 5 ANCC pharmacotherapeutic contact hours.

Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information
This activity will be remitted for ONCC/ILNA approval.

ACPE Accreditation Statement
The University of Texas at Austin College of Pharmacy Continuing Professional Development provided the ACPE accreditation for this course. The University of Texas at Austin College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.

ACPE Credit Designation Statement
This activity is approved for up to 0.05 CEU (5 contact hours) of continuing education credit. To receive 5 contact hours of CE credit, the participant must attend each session and complete the online evaluation. Upon successful completion of the course evaluation, the continuing pharmacy education credits will automatically be uploaded to CPE Monitor (allow 3 to 4 weeks for processing).

Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

Unlabeled/Unapproved Uses Notice
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the provider or grantors.

There is no implied or real endorsement of any product by Research To Practice, the Accreditation Council for Continuing Medical Education or American Nurses Credentialing Center. Any off-label use as declared by the FDA will be identified.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. Any individuals in a position to control the content of a CME/NCPD/ACPE-accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent reviewer (physician for CME, nurse for NCPD) for fair balance, scientific objectivity of studies referenced and patient care recommendations. Faculty disclosures to be provided.

FACULTY — Dr Shah has no relevant conflicts of interest to disclose. The following faculty reported relevant financial relationships with ineligible entities:

Dr Gainor — Advisory Committees: AI Proteins, Amgen Inc, ARS Pharmaceuticals, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Genentech, a member of the Roche Group, Gilead Sciences Inc, ITeos Therapeutics, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Mariana Oncology, Merck, Merus, Mirati Therapeutics Inc, Moderna, Novartis, Novocure Inc, Nuvalent, Pfizer Inc, Sanofi, Takeda Pharmaceuticals USA Inc; Consulting Agreements: Merck, Novartis, Pfizer Inc, Takeda Pharmaceuticals USA Inc; Contracted Research: Adaptimmune, ALX Oncology, AstraZeneca Pharmaceuticals LP, Blueprint Medicines, Bristol Myers Squibb, Genentech, a member of the Roche Group, Jounce Therapeutics, Merck, Moderna, NextPoint Therapeutics, Novartis, Palleon Pharmaceuticals; Nonrelevant Financial Relationships: AI Proteins. Dr Langer — Advisory Committees: Amgen Inc, Merck; Consulting Agreements: Aptitude Health, Boehringer Ingelheim Pharmaceuticals Inc, Catalyst Pharmaceuticals Inc, EMD Serono Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Merck, Pfizer Inc, Regeneron Pharmaceuticals Inc; Contracted Research (Institutional Support for Clinical Research): Amgen Inc, FUJIFILM Pharmaceuticals USA Inc, Novocure Inc; Data and Safety Monitoring Boards/Committees: Incyte Corporation, Summit Therapeutics; Nonrelevant Financial Relationships: Valor (VA). Dr Rogers — Advisory Committees: Genentech, a member of the Roche Group, Janssen Biotech Inc; Consulting Agreements: AbbVie Inc, Alpine Immune Sciences, AstraZeneca Pharmaceuticals LP, BeOne, Genentech, a member of the Roche Group, Lilly; Contracted Research: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Genentech, a member of the Roche Group, Lilly; Data and Safety Monitoring Boards/Committees: AstraZeneca Pharmaceuticals LP. Additional faculty to be announced.

MODERATOR — Dr Divers — Advisory Committees: Daiichi Sankyo Inc.

RESEARCH TO PRACTICE PRESIDENT NEIL LOVE, MD — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeOne, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Clovis Oncology, Coherus BioSciences, Corcept Therapeutics Inc, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Helsinn Therapeutics (US) Inc, Hologic Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Pharma America, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, and Tesaro, A GSK Company.

Research To Practice CME/NCPD/ACPE Planning Committee Members, Staff and Reviewers
Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

The Ritz-Carlton Dallas, Las Colinas
4150 N MacArthur Blvd
Irving, TX 75038
Hotel Phone: (972) 717-0700

Meeting Room
Lantana Ballroom — Lobby Level

Hotel Room Reservations

• • American Oncology Network (AON) members, please be sure to book accommodations in the AON room block.
• • For all other registrants, room reservation information will be included with the confirmation email after you have registered for this program.

 

Map: